title: Ameloblastoma of the jaws: Management and recurrence rate.
abstract: BACKGROUND
  Ameloblastoma is a rare, benign odontogenic tumour associated with a high recurrence rate. It accounts for 1% of all tumours of the jaws. The purpose of this study was to compare the ameloblastoma recurrence rate according to the type of treatment: radical or conservative.
  
  
  METHODS
  All patients with a diagnosis of ameloblastoma between 1991 and 2013 were retrospectively identified in order to extract topographic, radiological, and histological data and the type of treatment: conservative (marsupialization, enucleation, curettage) or radical (segmental resection) and to compare the recurrence rate according to the type of treatment.
  
  
  RESULTS
  Twenty-seven patients were included, managed by conservative treatment (CT) in 22 cases and radical treatment (RT) in 14 cases. The recurrence rate was 90.9% in the CT group and 9.1% in the RT group (P=0.025) with a mean follow-up of 56.2 months.
  
  
  CONCLUSIONS
  The recurrence rate after conservative treatment was higher than that after radical treatment. These results are similar to those reported in the literature. The choice of treatment must be adapted to the macroscopic and histological characteristics of each tumour and to the patient.
authors: CHU de Lille, Hôpital Roger-Salengro, Oral and Maxillofacial Surgery Department, 59000 Lille, France; Université Lille Nord de France, UDSL, 59000 Lille, France. Electronic address: amelyla@hotmail.com.
authors: A
authors: A
authors: Laborde
authors: CHU de Lille, Hôpital Roger-Salengro, Oral and Maxillofacial Surgery Department, 59000 Lille, France; Université Lille Nord de France, UDSL, 59000 Lille, France.
authors: R
authors: R
authors: Nicot
authors: Centre Oscar-Labret, Head and Neck Department, 59000 Lille, France; Inserm U 1008, Controlled Drug Delivery Systems and Biomaterials, 59000 Lille, France; International Association of Oral and Maxillofacial Medecine (IAOMM), 7, bis rue de la créativité, 59650 Villeneuve d'Asq, France.
authors: T
authors: T
authors: Wojcik
authors: CHU de Lille, Hôpital Roger-Salengro, Oral and Maxillofacial Surgery Department, 59000 Lille, France; Université Lille Nord de France, UDSL, 59000 Lille, France; Inserm U 1008, Controlled Drug Delivery Systems and Biomaterials, 59000 Lille, France; International Association of Oral and Maxillofacial Medecine (IAOMM), 7, bis rue de la créativité, 59650 Villeneuve d'Asq, France.
authors: J
authors: J
authors: Ferri
authors: CHU de Lille, Hôpital Roger-Salengro, Oral and Maxillofacial Surgery Department, 59000 Lille, France; Université Lille Nord de France, UDSL, 59000 Lille, France; Inserm U 1008, Controlled Drug Delivery Systems and Biomaterials, 59000 Lille, France; International Association of Oral and Maxillofacial Medecine (IAOMM), 7, bis rue de la créativité, 59650 Villeneuve d'Asq, France.
authors: G
authors: G
authors: Raoul
mesh_terms: D000564:Ameloblastoma / Q000473:pathology* / Q000601:surgery; D000072700:Conservative Treatment / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007573:Jaw Neoplasms / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D012189:Retrospective Studies
keywords: Ameloblastoma; Odontogenic tumours; Recurrence